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To estimate whether laxatives prescribed for constipation in Parkinson’s disease (PD) could moderate rigidity. Constipation
predates diagnosis of PD by decades. Deposition of misfolded protein may begin in the gut, driven by dysbiosis. Successive
antimicrobial exposures are associated with cumulative increase in rigidity, and rigidity has biological gradients on circulating
leukocyte-subset counts.
METHODS
Retrospective service evaluation, in a gut/brain axis clinic, yielded an interrupted time series, relating maintenance laxative and
other medication to rigidity, in consecutive outpatients identiﬁed by inclusion and exclusion criteria. Objective assessment of
rigidity was used to bring greater sensitivity to change, validated against subjective gold standard (UPDRS).
RESULTS
There were 1493 measurements of torque required to extend (ﬂexor rigidity) and ﬂex (extensor rigidity) the forearm in 79 PD
patients over 374 person-years. Both were strongly associated with UPDRS (P < 0.001 and P = 0.008, respectively). Before exhi-
bition of laxative, ﬂexor rigidity increased by 6% (95% CI 1, 10) per year, plateauing at2% (4, 1) per year after, with no shift at
initiation. Change in slope was signiﬁcant (P = 0.002), and manifest in those naïve to antiparkinsonian medication. The change
was replicated for individual laxative classes (bulk, osmotic, enterokinetic). There was no temporal change in extensor rigidity.
Limited experience with a quanylate cyclase-C receptor agonist (17 patients, 6 person-years) indicated a large and signiﬁcant step
down in ﬂexor and extensor rigidity, of 19% (1, 34) and 16% (6, 24) respectively (P = 0.04 and <0.001).
CONCLUSIONS
Maintenance laxative usage was associated with apparent stemming of the temporal increase in rigidity in PD, adding to
indicative evidence of a continuing role of gastrointestinal dysbiosis in pathogenesis.© 2016 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd
on behalf of The British Pharmacological Society.
DOI:10.1111/bcp.12967
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
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A. D. Augustin et al.WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Constipation markedly affects the quality of life in Parkinson’s disease (PD), and predates diagnosis by decades.
• The majority of PD patients have small intestinal bacterial overgrowth at presentation, probably a consequence of caeco-ileal reﬂux.
• There are biological gradients of quantiﬁed rigidity on circulating inﬂammatory markers: improving transit may protect.
WHAT THIS STUDY ADDS
• Flexor rigidity increased by a clinically signiﬁcant amount year-on-year before exhibition ofmaintenance laxatives, plateauing thereafter.
• A similar pattern was seen with bulk, osmotic and enterokinetic laxatives, pointing to a common mechanism.
• In contrast, linaclotide, which increases gastrointestinal secretion, was associated with a large step down in rigidity.Introduction
Parkinson’s disease (PD) is the second most common neuro-
degenerative disorder, with an estimated prevalence of 1%
in people aged over 60 years in industrialized countries [1].
James Parkinson noted the co-morbidity of constipation [2].
Constipation is more prevalent than PD in the general popu-
lation and, like PD, its prevalence increases with age [3, 4].
Prospectively, infrequent bowel movements are associated
with developing PD [5]. Retrospectively, frequency diverges
from that of controls three decades before the median age of
PD diagnosis [6]. Morbidity which predates diagnosis is more
likely to be closely linked to its aetiology, and to have drivers
and perpetuators in common.
In PD, aggregates of misfolded α-synuclein (Lewy bodies)
are found throughout the enteric nervous system from upper
oesophagus to rectum, in coeliac and para-vertebral sympa-
thetic ganglia, and in the dorsal vagal nuclei (which serve
the gastrointestinal tract) [7, 8]. Enteric deposition occurs
early in PD, even predating diagnosis [9–12]. In the brain, ag-
gregation ‘spreads’ through closely interconnected regions,
from brain stem to substantia nigra, areas of midbrain and
basal forebrain, eventually reaching the neocortex [13]. It
has been postulated that there is analogous spread from gut
to brain, via the vagus, through an uninterrupted series of
susceptible neurons. Indeed, a sub-population of α-synuclein
expressing myenteric neurons, synaptically connected to va-
gal efferents, has been described in rodents [14].
It is not known what initiates or ‘seeds’ misfolding of
α-synuclein, converts containment to progression, or drives
progression in PD. Although puriﬁed monomeric α-synuclein
can aggregate to form ﬁbrils in vitro, it required introduction
of ﬁbrils to produce insoluble aggregates in cultures of neu-
rons overexpressing α-synuclein [15]. Enteric α-synuclein
aggregates are described in clinical and experimental colitis
[16], that is with local inﬂammation in the gut. Lewy bodies
are not the ﬁrst manifestation of neurodegeneration: reduced
tyrosine hydroxylase immunoreactivity in the substantia
nigra is present before ‘spread’ of Lewy bodies from caudal
brain stem [17]. In early PD, inﬂammation in the affected
nigro-striatal pathway (measured by imaging microglial
activation) accompanies loss of presynaptic dopamine trans-
porter [18], becoming more widespread on follow-up [19]. In
advanced disease, histopathology shows persistent microglial
activation despite marked neuronal loss [20]. Thus, inﬂam-
mation may be a primary process, not just secondary to
neuronal death. Indeed, a systemic process would better ex-
plain the synucleinopathy, not just in cholinergic but also2 Br J Clin Pharmacol (2016) •• ••–••in vasoactive intestinal peptide and dopaminergic neurons
of the enteric nervous system, and in sympathetic ganglia,
including cardiac innervation [7, 8]. Moreover, circulating
inﬂammatory markers may represent peripheral drivers of
central neuroinﬂammation, since they are associated with se-
verity of cardinal facets of established PD [21–24] and predict
incident PD. There is a higher concentration of interleukin-6
in blood collected 4 years prior to PD diagnosis [25]. Hence
emerging therapeutic strategies to prevent, contain and clear
α-synuclein depositionmay be jeopardized by persistence of a
peripheral driver. This is likely to emanate from the gastroin-
testinal tract, or a stimulus related to it in the immuno-
inﬂammatory or metabolic milieu [26].
Bradford Hill [27] wrote ‘The clear dose–response curve
admits of a simple explanation’: implication causality. We
have found biological gradients of immuno-inﬂammatory
milieu and of exposome (i.e. environmental exposures) on
objectively measured rigidity in PD. Small intestinal bacterial
overgrowth in PD, which is a common accompaniment of the
slow gastrointestinal transit, is associated with higher circu-
lating natural killer cell and total CD4+ counts, and there is
a biological gradient between ﬂexor rigidity and natural killer
count, modulated by total CD4+ count [24]. (CD4+ subset in-
cludes regulatory T-cells which inhibit natural killer effector
mechanisms.) Moreover, successive courses of antimicrobials
are associated with a cumulative increase in ﬂexor rigidity,
over and above the effect of time, and irrespective of indica-
tion [28]. Repeated antimicrobial interventions might pro-
gressively increase dysbiosis in the ‘fermentation bioreactor’
of the right colon, with adverse immunological, immune-
regulatory and/or metabolomic consequences [29].
Conversely, improving intestinal transit by maintenance
laxatives may, by moderating dysbiosis, protect against rigid-
ity. Understanding the development of disease-speciﬁc path-
ophysiology clearly requires long-term observation. Service
evaluation of laxative usage is a potential tool, provided doc-
umentation of rigidity is adequate. This condition obtains in
our gut/brain axis clinic.Methods
Service evaluation setting and design
The setting is a gut/brain axis clinic, with a focus on PD and
an emphasis on quantifying disease facets to document
temporal change and response to treatment. Consecutive
patients exhibiting parkinsonism, attending between August
2002 and July 2014, were potential candidates for the
Laxatives and rigidity of Parkinson’s diseaseretrospective service evaluation (audit). Number of patients
entered and time over which each was evaluated were deter-
mined by availability of objective measurement of rigidity
and the inclusion and exclusion criteria. For inclusion, diag-
nosis of idiopathic PD was made according to UK Brain Bank
Criteria, with at least three supportive criteria, and exclusion
of other causes of parkinsonism [30]. Responsiveness to large
doses of levodopa was not a requirement. Presentation to the
clinic with moderate or severe levodopa-associated motor
ﬂuctuations [31] was an exclusion, so that longer term motor
effects were not confounded by within-day swings. Any data
obtained after onset of such ﬂuctuations were censored.
Patients using sedatives or anti-dopaminergic medication
were excluded. Those using stimulant laxatives were
excluded, because of the risk of colonic damage with long-
term use [32] and the need, where small intestinal bacterial
overgrowth is common, to speed small intestinal, as well as
colonic, transit. Since there is no standard checklist for
service evaluation, reference was made, where relevant, to
the TREND checklist for nonrandomized evaluations [33].
Criteria for use of laxatives and treatment
protocol
All PD patients were encouraged to have adequate ﬂuid intake
and a high residue diet. At each visit, they were questioned
about frequency of defecation, form and consistency of stool,
and common intestinal symptoms (abdominal discomfort
and pain, bloating, distension and ﬂatus, straining, feeling
of incomplete evacuation and sudden urge to defecate). Phys-
ical abdominal examination was made. Where the history
suggested spurious diarrhoea from colonic faecal overload,
abdominal X-ray was requested.
The decision to assign to laxative treatment was based on
severity of clinical picture, not time-span as used in diagnosing
idiopathic functional constipation (three months’ symptoms
within preceding year criterion) [34]. Initial maintenance treat-
ment was with bulk or osmotic laxative. Where the picture
did not improve, this was followed by both combined, and
then (since it became licensed) by adding the enterokinetic, se-
rotonin 5-HT4 receptor agonist, prucalopride (1 mg daily for 2
weeks, then 2 mg daily if tolerated). Laxative class, individual
agent/formulation within bulk and osmotic classes, and dos-
age were adjusted to achieve maximum efﬁcacy with tolerabil-
ity, taking account of patient preference. More recently, the
quanylate cyclase-C receptor agonist, linaclotide, was pre-
scribed, alone or as an adjuvant, only if irritable bowel
syndrome with constipation (IBS-C) had been diagnosed by
Rome II criteria [34]. (Linaclotide is currently approved in the
US to treat either chronic idiopathic constipation or IBS-C,
restricted to latter indication in Europe.) Guanylate cyclase-C
activation stimulates chloride and bicarbonate secretion and
inhibits sodium absorption, thereby increasing water ﬂow into
the intestine and speeding transit.
Strategy for use of antiparkinsonian and other
relevant medication
Need to introduce or modify antiparkinsonian medication
was according to doctor’s and patient’s perception of the
impact and progression of the disease, with reference to NICE
guidelines. We sought to avoid motor complications oflevodopa by using longer t1/2 medication for as long as this
did not impair quality of life. In feedback to the general prac-
titioner, maintenance laxatives were tabulated, alongside any
antiparkinsonian, β-adrenoceptor antagonist (for tremor) or
antidepressant medication. Patients were questioned as to
what medication they were actually taking at each visit.
Antimicrobial courses initiated between visits were not
recorded routinely throughout, unless relevant to the discus-
sion or spontaneously reported.
Outcomes
Usual practice in clinic is to measure upper limb rigidity ob-
jectively, on the side judged clinically to be more rigid at pre-
sentation [35]. Torque, required by an electric motor, to move
the relaxed supported forearm horizontally, through a 40° arc
about the elbow at a controlled velocity, is measured. Greater
resistance to passive movement in ﬂexor than in extensor
muscles is characteristic of parkinsonism, that is ‘ﬂexor rigid-
ity’ is greater than ‘extensor rigidity’. The former is repre-
sented by the grand mean for torque required to extend, the
latter by that to ﬂex. Swing duration is 1.3 s, with sampling
every 25 ms, the pause between swings varying (1–3 s) to re-
duce the effect of anticipation. One minute’s acclimatization
precedes the 2½ min recording. There was no temporal drift
in calibration values. Unshod weight and height (potential
between-patient covariates) are measured at each visit. For
the service evaluation, raw torque/time outputs were
reprocessed by an observer blind to date and medication.
Although an objective continuous measure of rigidity
should be more sensitive to change than a categorical clinical
predictor, the United Parkinson’s Disease Rating Scale
(UPDRS) scores are the current gold standards. UPDRS scores
(0–4) for rigidity in the upper limbs and neck and for
pronation-supination movements of hands are recorded on
the great majority of visits.
Outcomes are discussed with the patient, alongside the
fuller clinical picture, to inform management.
Statistical analysis
Association between paired objective and subjective mea-
sures was tested using Gaussian linear mixed regression
models. Objective rigidity measurements are positively
skewed and, thus, a natural logarithmic transformation was
applied prior to their use as an outcome variable. Patient-
speciﬁc intercepts were included, as a random effect, to
account for dependencies due to repeatedmeasurements over
time in each patient. The ﬁxed-effect predictor variables,
‘subjectivemeasurement’ and ‘patient-speciﬁc time since ﬁrst
measurement’, were included. The model was ﬁtted using
maximum likelihood, assuming an independent variance–
covariance structure. TheWald test was used to assess the null
hypothesis of no association between the subjective and
objective assessment, after adjusting for any temporal trend
in the objective.
Gaussian linear mixed regression models were used to es-
timate the impact of any maintenance laxative medication
on rigidity, as assessed objectively. Linear splines, correspond-
ing to the time periods before and after laxative initiation,
with a knot at initiation, were used to estimate change in
temporal disease progression. To allow for a potential ‘shift’Br J Clin Pharmacol (2016) •• ••–•• 3
Table 1
Characteristics at start of period evaluated in 79 patients
Characteristic Description
Demographic Age (years)* 66 (55 to 69)
Gender (male)† 45
Height (m)‡ 1.69 (0.10)
Weight (kg)‡ 75.2 (13.6)
Time since diagnosis
(years)*
2.8 (0.8 to 5.4)
Hoehn and Yahr
staging (1/2/3/4/5)†
17/50/6/5/1
Antiparkinsonian
medication
Any (yes)† 36
Dopaminergic agonist 26
Monoamine oxidase-B
inhibitor
25
Amantadine 8
Levodopa combination 15
A. D. Augustin et al.in rigidity at initiation, an indicator variable of pre/post initi-
ation was included in the model. Individual classes of laxa-
tive were investigated, allowing for any confounding by
inclusion of the other classes as covariates. Random inter-
cepts for each patient and independent random coefﬁcients
for temporal trends, prior to and post initiation, were in-
cluded. Antiparkinsonian and other relevant medications
were incorporated as time-varying covariates to allow for
any effect that they may have on rigidity. Models were ap-
plied also to the restricted subset of data from patients not re-
ceiving these medications, where no such confounding
effects could occur. Model predictions and standard errors
for ﬁxed effects were obtained directly from the model’s pa-
rameter and variance–covariance matrix estimates. Mixed ef-
fects ordered logit models were used to assess any change in
temporal trend in subjective rigidity measurements after ini-
tiating laxatives.
Insufﬁcient time post-initiation of the quanylate
cyclase-C receptor agonist precluded an assessment of its
impact on the temporal trend in rigidity. An estimate of
the relative change post-initiation was obtained in a
random coefﬁcient model with a single temporal trend for
each patient.
All statistical analyses were performed in Stata/MP 13.0.Anticholinergic 18
Laxative Any (yes)† 10
Bulk 9
Osmotic 5
Other 0
β-blocker Propranolol† 3
Antidepressant Citalopram† 4
*Median (interquartile range). †Count. ‡Mean (SD).Results
Characteristics of patients included
Table 1 gives the characteristics of 79 PD patients meeting the
selection criteria, at the start of their period of evaluation.
During their evaluation period, the 79 had 1493 measure-
ments [mean 18.9 (SD 13.5) per person] of each ﬂexor and
extensor rigidity over a median of 4.4 (interquartile range
2.4–7.0) years, a total of 374 person-years. Table 2 gives exposure
to bulk-forming (ispaghula husk/methylcellulose/sterculia),
osmotic (macrogols) and enterokinetic (prucalopride) laxatives
during the evaluation period. The corresponding pre- and
post-intervention measurements are summarized in Figure 1.
The relatively short exposure to a guanylate cylase-C receptor
agonist (linaclotide) and related measurements are summa-
rized in Figure 2.
Exposure to antiparkinsonian medication [dopaminergic
agonists (pramipexole, cabergoline), monoamine oxidase-B
inhibitor (selegiline), anticholinergic (trihexyphenidyl, with
a maximum total daily dose, 6 mg, at lower end of usual
range), levodopa combination (with extracerebral dopa-
decarboxylase inhibitor ± catechol-O-methyl transferase in-
hibitor), antidepressants (citalopram) and β-adrenergic recep-
tor antagonist (propranolol) during this period is also shown
in Table 2. A total of 104 antimicrobial courses were recorded
in 58 patients: one course in 28 patients, two in 14 and three
in 16.Validation of objective against subjective
assessment
Table 3 summarizes overall tests of signiﬁcance of association
between objective measures of rigidity and paired-
observations on the categorical predictors, UPDRS scores.4 Br J Clin Pharmacol (2016) •• ••–••All subjective assessments of rigidity (except on less-affected
upper limb) were indicative of measured ﬂexor and extensor
rigidity. For example, there was a 7.5% (95% CI 2.5–12.7) rel-
ative increase in ﬂexor rigidity between slight (score 1) and
none (0), a 48.2% (20.9–81.8) between severe (score 4) and
none (0). Similarly, there were 6.4% (1.0–12.1) and 41.4%
(13.0–76.9) relative increases in extensor rigidity between
scores 1 and 0, and 4 and 0, respectively. The pronation-
supination score on the more affected side was indicative of
measured ﬂexor and extensor rigidity, on the less affected side
only of ﬂexor rigidity.
Temporal trend in rigidity before and after the
initiation of laxatives
Table 4a shows the 5.5% per year increase in ﬂexor rigidity be-
fore maintenance laxatives were introduced, and plateauing
after. The difference in slopes was statistically signiﬁcant
(P = 0.002). There was no shift in rigidity at the time of inter-
vention. In contrast, there was no change in temporal trend
for extensor rigidity. The ratio of objectively measured ﬂexor
to extensor rigidity reﬂected the pattern for ﬂexor rigidity.
The time-varying covariates, class of antiparkinsonian medi-
cation, β-blocker and antidepressant medication and antimi-
crobial courses, had no signiﬁcant effect on ﬂexor rigidity at
Table 2
Exposure to laxative, antiparkinsonian, antidepressant and β-adren-
ergic during period evaluated in 79 patients
Data
Number of
patients
Median time
interval
(interquartile
range) years
Person-
years
Maintenance
laxative(s):
60 3.2 (1.1, 5.1) 209
bulk-forming 59 2.9 (1.0, 5.0) 199
osmotic 56 2.8 (1.1, 4.4) 176
enterokinetic 25 1.9 (0.7, 2.6) 43
Antiparkinsonian
agent(s):
dopaminergic
agonists
48 3.3 (2.1, 6.8) 206
monoamine
oxidase-B
inhibitor
48 3.4 (1.1, 6.5) 195
anticholinergic 31 4.5 (2.4, 7.6) 151
levodopa
combination
31 3.5 (2.3, 6.6) 127
amantadine 24 3.0 (1.8, 6.9) 95
Antidepressant 13 3.6 (0.7, 9.7) 66
Β-adrenergic
receptor
antagonist
11 4.0 (0.6, 4.6) 38
Laxatives and rigidity of Parkinson’s diseasethe 0.05 level. No important interactions between laxative
and antiparkinsonian medication on ﬂexor rigidity were ob-
served. The UPDRS categorical rating of ‘rigidity’ proved in-
sensitive to the change.
Table 4b shows that the temporal increase in ﬂexor rigid-
ity of PD was no longer observed following introduction of
maintenance laxative. This apparent stemming of progres-
sion was similar for bulk, osmotic and enterokinetic laxative
classes. On exhibition of osmotic laxative, there appeared to
be a downward shift in rigidity (7%, P = 0.06). Figure 1 shows
these ﬁndings in time perspective: proﬁles for these individ-
ual laxative classes were similar to those for any maintenance
laxatives.
The ﬁndings were replicated in data obtained whilst
patients were naïve to antiparkinsonian, β-blocker and anti-
depressant medication and without antimicrobial courses.
Over a third of rigidity measurements had been made prior
to receipt of such medication (558 measurements in 44
patients [mean 12.7 (SD 11.6) per person] over a median pe-
riod without laxative therapy of 1.4 (interquartile range
0.5–4.5) years, 119 person-years). The core analysis showed
a 7.8% (95% CI 3.2–12.5) per year increase in ﬂexor rigidity
(P < 0.001) before laxatives were introduced, no increase
(2.7% (3.4–9.2), P = 0.4) after, no shift on initiation. Again,
there was no change in temporal trend for extensor rigidity.
Figure 2 shows the change in rigidity in response to exhi-
bition of linaclotide over a median of 4.5 months, a total of 6person-years. The relative change was large and seen in exten-
sor as well as ﬂexor rigidity: 18.7% (0.6–33.6) (P = 0.04)
for ﬂexor and 15.7% (6.4–24.0) (P < 0.001) for extensor
(after adjustment for time and relative changes with other
medicinal interventions). Rigidity was no higher when
linaclotide was introduced than at introduction of other lax-
atives: the scope to respond was not greater for linaclotide.Discussion
Synopsis of key findings
We report an unyielding increase in ﬂexor rigidity, of on
average 5.5% per year, prior to introduction of laxatives. This
was despite capture of patients early in PD (when over half
were untreated) and intensive structured review of treatment
(average follow-up interval 2½ months, when on-demand
visits are included). Extensor rigidity was stable, so the
ﬂexor/extensor ratio increased: this is compatible with wors-
ening of ﬂexed posture. Exhibition of maintenance laxatives
was associated with loss of temporal increase in ﬂexor rigidity,
even in those naïve to antiparkinsonian medication.
The similar pattern occurring with bulk, osmotic and
enterokinetic laxatives pointed to a common mechanism of
action on rigidity, dependent on increasing intestinal transit
and/or reducing faecal overload. The enterokinetic agent
would have also promoted gastric emptying [36], but there
was no evidence that this was important. Early experience
with introducing maintenance quanylate cyclase-C receptor
agonist points to a different pattern of response: a large
downward shift in both ﬂexor and extensor rigidity, 17.2%
(on average) with a median of 4½ months’ exposure.Strengths and limitations in context of
literature
Controlled trials of laxatives in idiopathic chronic constipa-
tion tend to be of short-term monotherapy. This service
evaluation is analogous to an intention-to-treat, open inter-
vention study over years, albeit that the laxatives were
intended to treat constipation not rigidity. That is, the
expected outcome was on a comorbidity not a cardinal sign.
A limitation is the lack of a randomized comparator. However,
the gold standard of a long-term prospective, placebo-
controlled, randomized comparison presents ethical and
practical difﬁculties. Since slow gastrointestinal transit is in-
trinsic to PD, a parallel arm without laxatives is not a long-
term option. Using a placebo to evaluate laxative treatment
in PD, even over weeks, requires a ‘rescue medication’ proto-
col [37, 38]. Where the primary outcome is stemming the
increase in rigidity over years, a more realistic comparison
may be between ‘standard clinical care with pro re nata (prn)
laxatives’ and ‘actively and meticulously managed, tailored
maintenance schedules within ﬁxed protocols’.
Objective quantiﬁcation of rigidity allows titration of
maintenance therapy [35, 39], at successive visits. It has the
advantage of lack of observer bias, clearer deﬁnition of mag-
nitude, greater sensitivity to change, and separating ﬂexor
and extensor rigidity to give a physiological explanation of
posture. A placebo effect is extremely unlikely. This is not aBr J Clin Pharmacol (2016) •• ••–•• 5
Figure 1
Time trends and 95% CI in ﬂexor rigidity in relation to initiation of laxative classes at time 0. Of 1493 measurements in 79 patients, post-interven-
tion time trends are based on 811 measurements (mean 13.5 (SD 10.3) per person) of ﬂexor-rigidity in 60 receiving any laxative(s), 781 (13.2
(10.3)) in 59 receiving bulk laxative, 686 (12.3 (9.09)) in 56 receiving osmotic laxative, and 191 (7.6 (4.9)) in 25 receiving enterokinetic laxative.
Time trends pre-intervention with any laxative and with bulk, osmotic and enterokinetic laxatives are based on the residual 682, 712, 807 and
1302 measurements, respectively
A. D. Augustin et al.performance test, where subjects could ‘pull themselves to-
gether’ after, say, introducing maintenance laxative. (More-
over, it is difﬁcult to envisage physiologically how subjects
could counteract, over years, the temporal increment in resis-
tance to passivemovement as PD progresses.)We suggest that
long-term objective monitoring of rigidity should be adopted
widely, and to this end present the validation of our method-
ology against relevant categorical predictors (UPDRS).
Although the current statistical analysis takes account of po-
tential confounding by treatments relating to PD, information
on antimicrobial courses from general practice is incomplete,
and no information on other modalities (e.g. physiotherapy),
judged unlikely to affect rigidity per se, is included.
Comparative studies with focus on objective quantiﬁca-
tion of rigidity would help establish commonality and differ-
ences in laxative effects. There has been no prospective study
of prescription of linaclotide for constipation in PD, setting
the scene for discovery of its wider effects on the syndrome.6 Br J Clin Pharmacol (2016) •• ••–••No change in rigidity was noted in a placebo-controlled trial
of lubiprostone (a chloride channel activator which also
increases gastrointestinal ﬂuid secretion) for constipation in
52 PD patients [40]. However, only UPDRS ratings were used
and exposure was for just 4 weeks.Proposed mechanism and crucial future
research directions
Our work indicates a potential new approach to the manage-
ment of rigidity, opening the door to pragmatic and explor-
atory cause/effect studies. It uses on-the-shelf-medication.
Given that constipation occurs early in the natural history,
maintenance laxative usage has potential to be an initial ther-
apeutic strategy for rigidity, as well as an adjuvant to conven-
tional symptomatic treatment.
Since the loss of temporal increment in rigiditywas observed
in patients naïve to antiparkinsonian and other relevant
Figure 2
Changes in ﬂexor- and extensor-rigidity (in milli-Newton metres) after initiation of linaclotide in 17 patients. Pre-initiation, there were 329 mea-
surements of ﬂexor- and extensor-rigidity (mean 19 (SD 14) per person) over a median of 232 (interquartile range 100 to 346) weeks, and post-
initiation 48 sets (2 (1) per person) over 18 (6, 30) weeks
Laxatives and rigidity of Parkinson’s diseasemedications, a mechanism of laxative inﬂuence on drug phar-
macokinetics [41] ﬁnds no material support here. Laxatives
may reduce rigidity by moderating a gastrointestinal dysbiosis,
intrinsic to PD, or secondary to/exacerbated by the comorbidity
of constipation. The systemic immuno-inﬂammatory responseTable 3
Cross-referencing objectively measured rigidity against United
Parkinson’s Disease Rating Scale (UPDRS) scores using 1242 paired-
observations* in 79 patients
UPDRS item
Objectively measured rigidity on worse side
(n = 1240 paired measurements)
Flexor Extensor
P-value P-value
Rigidity upper
limb worse
side
<0.0001 0.008
Rigidity upper
limb better
side
0.1 0.4
Rigidity neck 0.004 0.02
Pronation-
supination
upper limb
worse side
0.006 0.04
Pronation-
supination
upper limb
better side
<0.0001 0.97
*UPDRS rating not applied, or applied by a different observer, on
27% of 1493 occasions when rigidity measured objectively.may be primarily mediated by the gut-associated lymphoid
tissue of the small intestine, but it is the colonic microbiota
which contribute most to the metabolomic output [29]. The
metabolome may have a direct toxic effect or inﬂuence
immune-regulation. Moderating the dysbiosis may lessen
neuroinﬂammation and this has a direct effect on rigidity, as
suggested by the biological gradient with circulating natural
killer count [24]. It may also downregulate a vicious cycle of
intraneuronal aggregation of misfolded α-synuclein, neuronal
death from cytotoxicity, its leakage from dead cells into the
extracellular space, and uptake into neighbouring cells with con-
sequent cytotoxic effect [8].
The gut microbiota has recently been described as ‘a world
once believed irrelevant but now looming large on the
Parkinson’s disease horizon’ [42], but interest goes back a long
way. For example, the path to aHelicobacter aetio-pathological hy-
pothesis [43] was paved by observation of an excess of previously
documented peptic ulcers in PD in 1965 [44] and the proposition
that an infectious agent was involved in both in 1979 [45]. This
was well before discovery of Helicobacter pylori-associated gastritis
in 1983 [46]. In a randomized controlled trial in PD, biopsy-
proven H. pylori eradication reduced hypokinesia on gait analysis
[47] (level of evidence is 1b as an individual trial). Hypokinesia
improved over the year post-eradication,with overall clinical ben-
eﬁt, but objective measurement revealed that rigidity worsened.
Both hypokinesia and rigidity plateaued over the next year. Im-
proved hypokinesia was independent of any (stable, long t1/2)
antiparkinsonian medication (receipt of levodopa an exclusion).
Tight surveillance of antimicrobial usage in PD showed the
hypokinesia effect to be indication-speciﬁc, the rigidity effect
non-speciﬁc [28]. Lack of integrity of commensal microbiota
maypredispose to failure of tolerance to particular foreign and self
antigens [48]. Indeed, there is evidence that adaptive
immunity/autoimmunity, as well as innate immunity withBr J Clin Pharmacol (2016) •• ••–•• 7
Table 4
Change in rigidity in relation to initiating maintenance laxative, based on 1493 measurements in 79 patients
(a) Effect of laxatives overall on ﬂexor and extensor rigidity and their ratio
Measurement
Change (% per year)*mean (95% CI) Shift (%) mean (95% CI)
Pre-intervention Post-intervention At intervention
Flexor rigidity 5.5 (1.4–9.7) 1.6 (3.8–0.7) 2.5 (8.6–4.0)
P-value 0.008 0.2 0.4
Extensor rigidity 1.1 (2.6–5.0) 0.9 (1.8–3.6) 2.4 (4.9–10.3)
P-value 0.6 0.5 0.5
Flexor/Extensor ratio 4.9 (0.8–9.2) 2.3 (4.9–0.3) 4.6 (11.3–2.7)
P-value 0.02 0.08 0.2
(b) Comparison of effect of different laxative classes on ﬂexor rigidity
Class of laxative
Change in ﬂexor rigidity (% per year)* mean (95% CI) Shift (%) mean (95% CI)
Pre-intervention Post-intervention At intervention
Bulk 5.2 (1.4–9.2) 1.2 (3.9–1.5) 0.7 (8.2–7.4)
P-value 0.007 0.4 0.9
Osmotic 4.5 (1.0–8.0) 0.1 (3.0–2.9) 6.8 (13.5–0.3)
P-value 0.01 0.9 0.06
Enterokinetic 2.6 (0.3–4.9) 0.7 (7.1–6.0) 0.4 (8.6–8.5)
P-value 0.02 0.8 0.9
*Adjusted for effects of time-varying covariates: antiparkinsonian medication by class, β-blocker and antidepressant medication and antimicrobial
courses.
A. D. Augustin et al.bystander damage, has a role in the pathogenesis [20, 26]. Since
H. pylori and hydrogen breath test positivity are inversely related
in PD [24], increased rigidity may ﬂag acquisition of small intesti-
nal bacterial overgrowth. However, hydrogen breath test per se did
not account for leukocyte associations with rigidity [24]. Other
measures of overgrowth, a component or non-bacterial associate
of overgrowth, or underlying colonic dysbiosis might.
Two approaches to deﬁning the gut microbiome in PD,
using 16S ribosomal RNA gene sequencing (studying 72
patients/72 controls and 38 patients/34 controls, respectively)
have been reported [49, 50], but with no consensus. Deﬁnitive
work is needed using whole genome sequencing to give greater
taxonomic resolution (species, and even strain, rather than
family/genus) and greater precision [51]. Sample size needs to
be adequate to characterize the microbiota of PD within a spec-
trum of neuropsychiatric and gastrointestinal disease, and in
terms of its facets and comorbidities. The control group needs
to be robust and well-characterized in these respects.
Metagenomic exploration should be set in context of the
immuno-inﬂammatory and metabolic milieu. Changes in
exposome and milieu associated with amelioration of rigidity
by laxative and other intervention need deﬁnition.Conclusions
The immediate therapeutic implication is thatmaintenance lax-
atives are disease-modifying in PD. The aetio-pathogenic impli-
cation is that change in the gut environment has a continuing8 Br J Clin Pharmacol (2016) •• ••–••and profound, but at least in part reversible, adverse effect.
Actively andmeticulouslymanaged, tailoredmaintenance laxa-
tive schedules within ﬁxed protocols, compared with standard
clinical care of prn laxatives, is a potential tool for exploring
the effect of exposome drivers and immuno-inﬂammatory and
metabolomic mediators on objectively measured ﬂexor rigidity.
Like other chronic diseases, PD is likely to be multistep,
multifactorial, but this does not preclude a systematic expla-
nation and interim clinical solutions. Targeting environmen-
tal inﬂuences has potential for cost-effective screening,
prophylaxis and amelioration. Indeed, the misfolded protein
theory of PD pathogenesis need not relegate any environ-
mental theory to being ‘hit-and-run’ and ‘remote’ in time.Competing Interests
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